Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
LEO Pharma
(https://skinoren.com) 📸 Data Snapshot: June 19, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Dermatology beyond the skin | LEO Pharma (https://skinoren.com)
Dermatology beyond the skin | LEO Pharma
HEADER_HEADING_REPEATED_BODY Our annual reporting | LEO Pharma (https://skinoren.com/our-annual-reporting/)
Our annual reporting | LEO Pharma
HEADER_HEADING Media | LEO Pharma (https://skinoren.com/media-center/)
Media | LEO Pharma
HEADER_HEADING Contact | LEO Pharma (https://skinoren.com/contact/)
Contact | LEO Pharma
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://skinoren.com) Dermatology beyond the skin | LEO Pharma
[IMG: Video Fallback] Play video [H1] Together, we reach far beyond the skin [H4] Putting innovation into practice with an extensive global portfolio of treatments in medical dermatology [H4] Lifting the burden of disease for nearly 100 million people who rely on our medicines every year [H4] Shaping the future of what’s next in partnership with healthcare organizations, scientists and patient groupsLearn more PRESS RELEASE [H2] LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while significantly increasing commercial investments to support the global roll-out of Anzupgo® and the addition of Spevigo® to the portfolio.Ballerup, Denmark, May 5, 2026Learn more [H2] MORE NEWS Jun 08 2026 LEO Pharma’s net-zero and emissions reduction targets validated by SBTiMay 07 2026 LEO Pharma lancerer LOQTORZI® (toripalimab) på hjemmemarkedet i DanmarkMay 05 2026 LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipelineAll News [IMG: Background] ANNUAL REPORT 2025 [H2] LEO Pharma delivers 10% revenue growth in 2025 and more than doubles adjusted EBITDA margin In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, and achieved a significant improvement in profitability, returning to positive net profit and free cash flow. Read more CAREER [H2] Discover how we innovate collectively. For us, collaborating innovatively means continuously enhancing and expanding what's achievable for one another, our company, and our patients.Learn more
SUB-PAGE (https://skinoren.com/our-annual-reporting/) Our annual reporting | LEO Pharma
HomeOur annual reporting ANNUAL REPORT 2025 [H1] Making a fundamental difference LEO Pharma's Annual Report covers our financial and sustainability reporting for the financial year from January 1 to December 31. [H1] LEO Pharma delivers 10% revenue growth in 2025 and more than doubles adjusted EBITDA margin In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, and achieved a significant improvement in profitability, returning to positive net profit and free cash flow. The portfolio was strengthened by the launch of Anzupgo® in 10 additional markets, including the U.S., as well as the addition of Spevigo®. The pipeline was advanced through new late‑stage programs and strategic partnerships aimed at accelerating innovation. For 2026, revenue growth is expected to be 8-11% (CER), supporting further improvement in the adjusted EBITDA margin to 16-19%, alongside increased investments in innovation and LEO Pharma’s global platform. [H2] Financial highlights LEO Pharma’s revenue increased by 10% at constant exchange rates (CER) and by 8% in DKK to 13,499 million. Revenue growth was led by North America (+35% at CER), with Rest of World (+9% at CER) and Europe (+3% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 12% (CER), driven by the Strategic brands Adtralza®/Adbry®, Anzupgo®, and Spevigo®, which combined had a revenue increase of 48% (CER), in addition to growth of 2% (CER) for the Established brands. Sales in the Critical Care portfolio declined by 1% (CER), affected by a reversal of sales discounts in the same period last year. Operating profit improved sharply, with adjusted EBITDA reaching DKK 2,107 million in 2025, reflecting a margin of 16% (2024: 7%), excluding the STAT6 partnership upfront payment from Gilead Sciences received in January 2025 and other non-recurring items. The improvement in adjusted EBITDA was driven by sales growth and reduced operating expenses. Net profit for 2025 was DKK 2,489 million (2024: negative DKK 1,776 million), including non-recurring items. Free cash flow was DKK 1,875 million for 2025 (2024: negative DKK 52 million), and net interest-bearing debt was reduced to DKK 9,347 million (2024: DKK 11,115 million). Excluding M&A, free cash flow was DKK 940 million. [H2] Innovation highlights Anzupgo® (delgocitinib) cream was launched in the U.S. in September as the first and only topical pan‑JAK inhibitor for chronic hand eczema, supported by a more than 50% increase in LEO Pharma’s U.S. sales force following FDA approval in July 2025. Spevigo® (spesolimab), an IL-36RA biologic for generalized pustular psoriasis, joined LEO Pharma’s portfolio on 30 September as its third global, first-in-class brand following a development and commercialization license secured from Boehringer Ingelheim. In 2025, LEO Pharma entered several strategic partnerships to advance innovation, including an agreement with Gilead Sciences for the pre-clinical STAT6 program. The pipeline was expanded with new late stage trials of Anzupgo® (delgocitinib cream) in adults with palmoplantar pustulosis and lichen sclerosus, as well as the addition of an ongoing Phase 3 trial of Spevigo® (spesolimab) in pyoderma gangrenosum. [H2] 2026 Outlook For 2026, group revenue growth is expected at 8-11% (CER) driven by Anzupgo® and Spevigo®. The adjusted EBITDA margin is expected to improve to 16-19%, led by gross margin expansion, offset by higher commercial investments and R&D. "2025 was another year of strong progress for LEO Pharma and a landmark year in our strategic transformation. We expanded our portfolio, delivered strong growth with significantly improved profitability, and formed new partnerships to accelerate innovation. With the ongoing launch of Anzupgo® and the addition of Spevigo®, we enter 2026 with strong momentum, committed to making a fundamental difference for patients by further unlocking the potential of our global platform,” said Christophe Bourdon, CEO of LEO Pharma. [H2] FY2025 Financial overview [IMG: Overview] [IMG: Cashflow] [IMG: Ebitda] [IMG: Revenue] DOWNLOAD [H1] Annual Report 2025 Read our Annual Report and Sustainability statement to learn more about our financial performance and progress on our Growth StrategyBallerup, Denmark, February 18, 2026Download [H1] Archive Annual Report 2024 (PDF) Annual Report 2023 (PDF) Annual Report 2022 (PDF) Annual Report 2021 (PDF) Annual Report 2020 (PDF) Annual Report 2019 (PDF) Annual Report 2018 (PDF) Annual Report 2017 (PDF) Annual Report 2016 (PDF) Annual Report 2015 (PDF) [H2] [H2] Sustainability / CSR reports From 2018-2020, we did not publish a separate Sustainability or CSR report. For these years, our CSR reporting was incorporated into our Annual Report. Find our previous CSR reports here: CSR Report 2022 (PDF) CSR Report 2021 (PDF) CSR Report 2017 (PDF) CSR Report 2016 (PDF) CSR Report 2015 (PDF) CSR Report 2014 (PDF) [H2] Environmental performance reports Please find our Environmental Performance Reports covering environmental data from our manufacturing sites at country level here: Corporate Environmental Performance Report 2020 (PDF) Corporate Environmental Performance Report 2019 (PDF) Corporate Environmental Performance Report 2018 (PDF) Corporate Environmental Performance Report 2017 (PDF) Corporate Environmental Performance Report 2016 (PDF) Corporate EHSE Report 2015 (PDF) Corporate EHSE Report 2014 (PDF) Corporate EHSE Report 2013 (PDF)
SUB-PAGE (https://skinoren.com/media-center/) Media | LEO Pharma
Media [H1] News & Insights When you have a passion for innovation and an aspiration to improve the lives of people with skin diseases, you are going to make some headlines. Learn about our latest news below. [H2] MORE NEWS Jun 08 2026 LEO Pharma’s net-zero and emissions reduction targets validated by SBTiMay 07 2026 LEO Pharma lancerer LOQTORZI® (toripalimab) på hjemmemarkedet i DanmarkMay 05 2026 LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipelineAll News [IMG: Background] [H1] In case you missed it [H2] Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases [H1] Our performance and results LEO Pharma delivers 10% revenue growth in 2025 and more than doubles adjusted EBITDA marginRead our 2025 Annual Report [H1] Images Explore our media library so you can put faces to names and see our state-of-the-art production facilities and offices.Go to Image Library [H2] Useful information Fact sheet A concise summary of LEO Pharma’s key information and achievements. Expect clear, straightforward data and essential insights. Global Leadership Team Get to know our top management team, featuring their expertise, accomplishments, and pivotal roles in driving LEO Pharma's success. MEDIA INQUIRIES [IMG: Jeppe Ilkjaer] [H4] Jeppe Ilkjaer Head of Media Tel: +45 30502014Get in touch [IMG: Anders] [H4] Anders Monrad Rendtorff SVP, Head of Corporate CommunicationsGet in touch [H2] Our press releases are intended for the media To comply with applicable regulation, product-related press releases are removed from our website within three weeks of publication. They are available upon request.. For updated information about clinical trials, please visit https://clinicaltrials.gov/ https://clinicaltrials.gov/. [H1] About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com
SUB-PAGE (https://skinoren.com/contact/) Contact | LEO Pharma
HomeContact [H1] Get in touch You can contact LEO Pharma A/S by filling in the following form. All fields marked with * must be filled in. [H2] Report a Speak-Up matter The LEO Pharma Speak-Up Line is a voluntary alternative to other communication channels to make it possible to come forward and disclose unethical behavior within LEO Pharma in a safe and confidential way. Reporting is possible in multiple languages 24 hours a day, 365 days a year by web as well as telephone. For more information on what can be reported and how to report, please click here. [H2] Report a product complaint If you would like to file a product complaint, please contact the responsible market where you have purchased our product. Contact details can be found by browsing our global directory. Contact can be made either by phone or email. By email, please fill in and attach the Complaint Form. [H1] Report side effects by email To report a side effect, you can write us at drug.safety@leo-pharma.com or fill in the webform ‘Public Reporting Form for Side Effects on LEO Pharma Products’ by following the link below. Public Reporting Form Side Effects LEO Pharma will keep and store your health data as long as required to meet our Pharmacovigilance obligations. You can submit anonymous data; but if you provide us with your contact details, you are entitled to request a copy of the information collected. The data will be stored according to LEO Pharma guidelines on data protection. Read more here.
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 2 | 1 |
| /our-annual-reporting/ | 8 | 1 |
| /media-center/ | 0 | 1 |
| /contact/ | 0 | 1 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "http://schema.org",
"@type": "WebSite",
"name": "LEO Pharma",
"url": "https://www.leo-pharma.com/"
}
/our-annual-reporting/
{
"@context": "http://schema.org",
"@type": "WebSite",
"name": "LEO Pharma",
"url": "https://www.leo-pharma.com/"
}
/media-center/
{
"@context": "http://schema.org",
"@type": "WebSite",
"name": "LEO Pharma",
"url": "https://www.leo-pharma.com/"
}
/contact/
{
"@context": "http://schema.org",
"@type": "WebSite",
"name": "LEO Pharma",
"url": "https://www.leo-pharma.com/"
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
LEO Pharma has 9.7 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: LEO Pharma (skinoren.com)
This is a high-substance corporate pharmaceutical site that uses fluff as a wrapper for hard clinical and financial data. While the headers are poetic and generic, the underlying evidence is forensic, dated, and highly auditable. The low BS score reflects a professional organization that backs its global leader claims with multi-billion dollar revenue figures and specific FDA milestones.
Replace fluff-heavy H1 and H4 headings with more descriptive, noun-based headers that highlight specific therapeutic areas or milestones. Implement Organization and MedicalOrganization schema with sameAs links to the LEO Foundation and executive LinkedIn profiles to close the authority gap. Add direct outbound links to ClinicalTrials.gov or PubMed for every drug mention in the innovation highlights section. Remove the repetitive making a fundamental difference phrase and replace it with more specific positioning regarding their focus on medical dermatology.
The content perfectly aligns with the Medical Devices, Pharma & Biotech category. It utilizes precise industry-standard financial metrics like CER (Constant Exchange Rates) and EBITDA, alongside clinical terminology such as pan-JAK inhibitor, IL-36RA biologic, and Phase 3 trials.
“The score of 31 is primarily driven by Commodity Fingerprint and Information Density (specifically heading fluff). The high volume of specific financial data and the presence of a 10-year report archive significantly suppressed the score in the Trust and Proof pillar. The technical credibility and cross-page consistency are high, resulting in a very low Semantic Coherence penalty.”
This training module utilizes a snapshot of public data from LEO Pharma, captured on June 19, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to LEO Pharma: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://skinoren.com to view the most current version of its content and learn from the source what this company is about and what it offers.